Clene Shares Move Higher On Encouraging Data From Multiple Sclerosis Candidate

Clene Inc CLNN announced updated MRI results from the Phase 2 double-blinded, 48-week treatment period of the VISIONARY-MS trial in multiple sclerosis (MS) patients.
These exploratory MRI results support the previously reported statistically significant clinical improvements in low contrast vision and global neurological function in stable relapsing MS patients reported in the mITT population.
Related: Clene's COVID-19 Candidate Shows No Substantial Symptom Resolution In Phase 2 Trial.
The MRI findings provide evidence of brain neuronal structural integrity assessed by diffusion tensor imaging (DTI), demonstrating statistically significant results for axonal integrity and white matter integrity, independent of an immunomodulatory effect.
MRI results showed improved brain neuronal structural integrity, independent of an immunomodulatory effect.
MRI results consistently favor CNM-Au8 improvement of neuronal integrity and myelin improvement, showing decreased brain deterioration.
CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by increasing energy production and utilization.
Price Action: CLNN shares are up 15.55% at $1.56 on the last check Monday.